Skip to main content
    W

    West Pharmaceutical Services Inc (WST)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $417.95
    +1.53 (+0.37%)

    Market Cap: $29.01B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    West Pharmaceutical Services Inc (WST) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    West Pharmaceutical Services (WST) trades at 45.4x trailing earnings and 8.9x sales. Its P/E of 45.4x is above its 5-year median of 40.4x. Its forward P/E is 41.8x. The median P/E across 12 similar companies is 18.2x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 8.6% higher over the next year. Its free cash flow yield is 1.5%.

    MultipleValue
    P/E (trailing)45.4x
    Forward P/E41.8x
    Price to sales8.9x
    Price to book9.9x
    EV/EBITDA34.1x
    Price to FCF67.7x
    EV/FCF67.2x
    PEG3.0
    FCF yield1.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 8.6% above 41.8x, its P/S is 30.9% above 6.8x and its P/B is 32.0% above 7.5x.

    MultipleCurrent5-year median10-year median
    P/E45.4x40.4x41.8x
    P/S8.9x8.0x6.8x
    P/B9.9x8.8x7.5x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 27.5x in 2022 to 59.6x in 2020.

    Year endPriceP/EP/SP/B
    2025$275.1437.7x6.5x6.3x
    2024$327.5648.5x8.3x9.0x
    2023$352.1243.6x8.9x9.2x
    2022$235.3527.5x6.1x6.6x
    2021$469.0154.5x12.4x15.3x
    2020$283.3159.6x9.8x11.6x
    2019$150.3346.4x6.1x7.2x
    2018$98.0334.9x4.2x5.3x
    2017$98.6738.4x4.6x5.9x
    2016$84.8338.7x4.1x5.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About WST

    What is WST's forward P/E ratio?

    West Pharmaceutical Services has a forward P/E ratio of 41.8x.

    Is WST stock overvalued?

    GNG's valuation label for WST is Undervalued. Its P/E of 45.4x compares with a median of 18.2x across 12 similar companies.

    What is WST's price to sales ratio?

    West Pharmaceutical Services has a price to sales ratio of 8.9x.

    What is West Pharmaceutical Services's average P/E ratio over 5 years?

    West Pharmaceutical Services's median P/E over the last 5 years is 40.4x, from 60 month-end values through Oct 2026.

    What is WST's PEG ratio?

    West Pharmaceutical Services has a PEG ratio of 3.0.